Abstract 334P
Background
Compared to global figures, breast cancer mortality to incidence ratio is worst in Sub Saharan Africa where about 80% of patients present with locally advanced and metastatic disease at diagnosis. In Cameroon, breast cancer is the commonest cancer with 4,170 cases recorded each year constituting 20.1% of all cancers diagnosed. Late disease presentation is attributed to poor awareness, absence of organized early detection programs, and inadequate facilities for accurate and timely diagnosis and treatment. Our objective was to investigate the role that nurses involved in cervical cancer screening/prevention can play in early detection of breast cancer in Cameroon.
Methods
The nurses involved in cervical cancer screening/prevention in a large faith-based healthcare organization called the Cameroon Baptist Convention Health Services (CBCHS) were trained to do clinical breast exams (CBE) for women aged 21 years and over, and also trained on breast tissue collection for pathology processing and examination. Clients with abnormal breast findings were provided Fine Needle Aspirations (FNA), TruCut biopsies or referred for ultrasound and/or mammography depending on the clinical presentation.
Results
Between January 2020 and December 2022, a total of 16,038 women age range (14-99) years were provided CBE with a mean and median age of 40.4 and 39, respectively. Among these, 750 (4.7%) had abnormal findings. Among those with abnormal findings, 397(52.9%) had breast masses for which 213 (53.7%) had TruCut biopsies and FNA and the others were either referred or had previously established diagnosis. From the 213 Tru-Cut biopsies and FNA’s done, 76 (35.7%) showed a pathology diagnosis of invasive breast cancer while the others showed: acute mastitis 3 (2.9%), fibroadenoma 25 (11.7%), benign mass 83 (39.0%), non-diagnostic 12 (5.6%) and other diagnosis 19 (8.9%).
Conclusions
Nurses can play a key role in early detection of breast cancer if they are trained, and this can greatly reduce the number of women seen with late stage disease and also reduce mortality rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
263P - Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data
Presenter: Layal Rached
Session: Poster session 02
264P - Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): Final analysis
Presenter: Sheyda Abdullaeva
Session: Poster session 02
265P - Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: A 10-year dual-center retrospective study
Presenter: Yijun Li
Session: Poster session 02
266P - Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis
Presenter: Francesca Schipilliti
Session: Poster session 02
267P - Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+ early breast cancer: Real-world data from NeoPowER study
Presenter: Fabio Canino
Session: Poster session 02
268P - Evaluating the efficacy of adjuvant capecitabine in triple-negative breast cancer patients with residual disease: A real-world evidence study
Presenter: Min Jeong Kim
Session: Poster session 02
269P - Achieving treatment goals in elderly breast cancer patients with neoadjuvant chemotherapy: A remarkable insight
Presenter: Eda Caliskan Yildirim
Session: Poster session 02
270P - Influence of neoadjuvant chemotherapy-induced short-term amenorrhea on pathologic response and treatment outcome in ER+HER2- breast cancer
Presenter: Seung Eun Lee
Session: Poster session 02
271P - First clinical demonstration of the predictive value of tissue nanomechanical signature in breast cancer patients in neoadjuvant therapy setting
Presenter: Sara Nizzero
Session: Poster session 02